Immunic Unveils Promising Vidofludimus Calcium Data at ECTRIMS Congress

Immunic, Inc. presented key findings on its lead asset, vidofludimus calcium, at the 40th Congress of ECTRIMS, held in Copenhagen. The interim analysis from the Phase 2 CALLIPER trial demonstrated that vidofludimus calcium consistently reduced neurofilament light chain levels compared to placebo across various age and disability levels in progressive multiple sclerosis subtypes.

Preclinical data also highlighted vidofludimus calcium's potential in improving neuronal survival through Nurr1 activation. Additionally, the drug showed promising antiviral effects, possibly reducing fatigue linked to Epstein-Barr virus reactivation, a common issue in multiple sclerosis.

The company aims to further assess these findings through ongoing trials, including the Phase 3 ENSURE and Phase 2 RAPID_REVIVE studies. "These results underscore vidofludimus calcium's potential to become a new treatment option for multiple sclerosis," stated Daniel Vitt, CEO of Immunic.